- Details
- In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors. Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in ea...
|
- Details
- Ashish Kamat discusses the importance of TURBT and its value for diagnosis, therapeutic and prognostic purposes as an essential part of multidisciplinary care with specific regards to clinical trials. Ashish also compares different agents for the detection of bladder cancer and how these agents are reflected in the AUA/SUO Guidelines. Biography: Ashish Kamat, MD, MBBS , President, International Bl...
|
- Details
- (Length of Discussion: 7 min) Evan Yu and Alicia Morgans provide a review of bladder cancer prevalence and epidemiology in current clinical trials. This interview also includes the Keynote-057 trial results leading to plans for a phase 3 trial for a more efficacious treatment strategy for these patients with less toxicities. Biographies: Evan Yu, MD Alicia Morgans, MD, MPH Related Content: Pembrol...
|
- Details
- (Length of discussion: 21 minutes) Maria De Santis and Alicia Morgans review the role of chemotherapy in genitourinary malignancies. This discussion evolves to appropriate patient selection, sharing clinical preference in dosing chemotherapy and their view of supportive care. Biographies: Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medic...
|
- Details
- (Length of Discussion: 16 min) Arjun Balar and Alicia Morgans discuss outcomes in bladder cancer trials with a focus on primary endpoints, duration of response, and adverse events. Trials to practice with accurate clinical staging may lead to the ultimate goal of organ conservation in this patient population. Biographies: Arjun Balar, MD is the director of the genitourinary medical oncology progra...
|
- Details
- (Length of Discussion: 12 min) Alicia Morgans and Josh Meeks highlight ongoing trials in non-muscle invasive bladder cancer. Reviews of SWOG 1602 and 1605, highlight the great work being done in the search for treatment options for patients with this disease, the ultimate hope for patients is to retain their bladder and potentially be cancer-free. Biographies: Joshua J Meeks, MD, Ph.D., is an Assi...
|
- Details
- (Length of Presentation: 10 min) Alicia Morgans, MD and Bishoy Faltas, MD have an energetic conversation about the tremendous progress they have seen in the recent years in bladder cancer. Dr. Faltas takes us through some of the current research with IO therapy, specifically checkpoint inhibition; where they are currently used and where the clinical data may expand the use of these agents. He revi...
|
- Details
- (Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...
|
- Details
- (Length of Discussion: 23 min) Petros Grivas and Alicia Morgans talk post-ASCO 2018 about a number of studies and abstracts presented. The first they review is the ABACUS study presented by Thomas Powles, MD. This single arm, phase II study investigated two cycles of atezolizumab (1200mg every three weeks) prior to radical cystectomy among patients with T2-4N0M0 urothelial carcinoma. The second st...
|
- Details
- (Length of Discussion: 16 min) Petros Grivas and Alicia Morgans discuss the late-breaking FDA Alert announcing the label changes for Pembrolizumab and Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1. Biographies: Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate c...
|
